Medtronic (NYSE:MDT) Updates FY 2026 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 5.620-5.660 for the period, compared to the consensus EPS estimate of 5.630. The company issued revenue guidance of -, compared to the consensus revenue estimate of $35.8 billion.

Medtronic Stock Performance

Shares of MDT stock opened at $100.83 on Wednesday. Medtronic has a 52-week low of $79.29 and a 52-week high of $102.48. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The stock has a market cap of $129.33 billion, a PE ratio of 27.78, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The business has a 50-day simple moving average of $94.64 and a 200-day simple moving average of $90.63.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts expect that Medtronic will post 5.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MDT. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. Citigroup lifted their price objective on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. UBS Group upped their price objective on shares of Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. Truist Financial increased their target price on shares of Medtronic from $96.00 to $103.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Finally, Leerink Partners set a $120.00 price target on Medtronic in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.41.

Insider Activity

In other news, Director William R. Jellison acquired 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.26% of the company’s stock.

Institutional Investors Weigh In On Medtronic

Hedge funds have recently modified their holdings of the business. Advisory Services Network LLC increased its holdings in shares of Medtronic by 4.5% in the third quarter. Advisory Services Network LLC now owns 79,432 shares of the medical technology company’s stock valued at $7,565,000 after purchasing an additional 3,400 shares during the last quarter. Financial Engines Advisors L.L.C. grew its stake in shares of Medtronic by 19.6% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,928 shares of the medical technology company’s stock valued at $279,000 after buying an additional 479 shares during the period. Morningstar Investment Management LLC increased its position in shares of Medtronic by 97.7% during the 3rd quarter. Morningstar Investment Management LLC now owns 44,991 shares of the medical technology company’s stock worth $4,285,000 after purchasing an additional 22,229 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Medtronic by 47.7% in the 3rd quarter. NewEdge Advisors LLC now owns 201,108 shares of the medical technology company’s stock worth $19,154,000 after acquiring an additional 64,905 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in Medtronic by 0.5% in the 3rd quarter. Armistice Capital LLC now owns 265,257 shares of the medical technology company’s stock valued at $25,263,000 after purchasing an additional 1,257 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.